Grand Pharmaceutical Group (HKSE:00512) Capex-to-Operating-Income : 0.21 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Grand Pharmaceutical Group Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Grand Pharmaceutical Group's Capital Expenditure for the six months ended in Dec. 2023 was HK$-269.15 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$1,288.42 Mil.

Hence, Grand Pharmaceutical Group's Capex-to-Operating-Income for the six months ended in Dec. 2023 was 0.21.

Grand Pharmaceutical Group Capex-to-Operating-Income Historical Data

The historical data trend for Grand Pharmaceutical Group's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group Capex-to-Operating-Income Chart

Grand Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Get a 7-Day Free Trial

0.43

0.16

0.27

0.40

0.18

Grand Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Operating-Income	Get a 7-Day Free Trial															0.23	0.18	0.63	0.15	0.21

Competitive Comparison of Grand Pharmaceutical Group's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grand Pharmaceutical Group's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's Capex-to-Operating-Income falls into.

Grand Pharmaceutical Group Capex-to-Operating-Income Calculation

Grand Pharmaceutical Group's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-497.689)	/	2823.293
	=	0.18

Grand Pharmaceutical Group's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-269.154)	/	1288.421
	=	0.21

Grand Pharmaceutical Group (HKSE:00512) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Grand Pharmaceutical Group Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Grand Pharmaceutical Group (HKSE:00512) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » Capex-to-Operating-Income

Traded in Other Exchanges

MX6A:Germany

Address

99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG

Website

http://www.chinagrandpharm.com

Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from China and also has a presence in America; Europe; Asia other than the PRC and others.

Executives

Shang Hai Yuan Da Chan Rong Tou Zi Guan Li You Xian Gong Si	2101 Beneficial owner
Hu Kaijun	2201 Interest of corporation controlled by you
East Ocean Capital (hong Kong) Company Limited	2101 Beneficial owner
Lion River I N.v.	2201 Interest of corporation controlled by you
Li Zhenfu	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.	2201 Interest of corporation controlled by you
Assicurazioni Generali Spa	2201 Interest of corporation controlled by you
Citic Group Corporation	2201 Interest of corporation controlled by you
Citic Limited	2201 Interest of corporation controlled by you
China Citic Bank Corporation Limited	2201 Interest of corporation controlled by you
Cncb (hong Kong) Investment Limited	2106 Person having a security interest in shares
Grand (hongkong) International Investments Holdings Limited
Chau Tung
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si
Outwit Investments Limited

Grand Pharmaceutical Group (HKSE:00512) Headlines

No Headlines